시장보고서

상품코드

1761175

세계의 DNA 플라스미드 제조 시장 : 시장 규모, 점유율, 동향, 성장 기회 분석 보고서 - 제품 유형별, 용도별, 최종 사용자별, 지역별(2021-2031년)

DNA Plasmid Manufacturing Market Size and Forecast 2021 - 2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product Type, Application, End User and Geography

발행일: 2025년 06월 | 리서치사:

The Insight Partners | 페이지 정보: 영문 222 Pages | 배송안내 : 즉시배송

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

DNA 플라스미드 제조 시장은 2024년 6억 8,638만 달러로 평가되었고, 2031년 26억 4,836만 달러에 이를 것으로 예측되며, 2025-2031년 CAGR 21.4%로 성장할 것으로 추정됩니다. 시장 성장을 가속하는 주요 요인으로는 유전자 치료용 플라스미드 개발 증가, DNA 플라스미드 백신 개발 연구 확대 등이 있습니다. 그러나, 제조 비용이 높은 것이 시장의 저해 요인이 되고 있습니다.

유전성 질환, 희귀질환, 기타 암의 유병률 증가는 유전자 치료 기술의 진보를 가속화하고 있으며, 이러한 기술은 기본 요소로서 플라스미드 DNA에 크게 의존하고 있습니다. 플라스미드 DNA는 환자의 세포에 유전 물질을 도입하는 데 도움이 됩니다. 플라스미드 DNA는 비바이러스성 벡터로 작용하여 결함 유전자를 복구하거나 대체하는 치료 유전자를 전달합니다. 바이러스성 벡터와는 달리, 플라스미드는 보다 안전하고, 제조하기 쉽고, 저렴하기 때문에 유전자 치료에 널리 사용되고 있습니다.

유전자 치료가 전임상 개발에서 임상시험, 상업적 출시로 전환됨에 따라 고순도, GMP 등급 플라스미드 DNA의 대량 수요가 현저하게 증가하고 있습니다. 2023년 3월, Charles River Laboratories International은 아데노 관련 바이러스(AAV) 기반 유전자 치료 프로그램의 조기 발견부터 상업 생산에 이르는 공급 확보 및 간소화를 목적으로 하는 기성품 헬퍼(Helper Plasmid)를 제공하기 시작했다고 발표했습니다.

유전자 치료 파이프라인의 품질과 규제 요구를 충족시키기 위한 기업 간의 파트너십 확대. 2022년 마텔과 포지 바이오로직스는 바이러스 벡터와 플라스미드 DNA의 cGMP 제조 파트너십을 발표했습니다. 포지사는 마텔사의 프로그램인 Myr-201(단발성 난청을 위한 신규 유전자 치료)을 위해 연구 등급 및 GMP 패스웨이의 플라스미드 제조 서비스, cGMP 아데노 수반 바이러스(AAV) 프로세스 개발 및 스케일업 제조 서비스를 제공합니다.

정부와 규제 당국은 또한 유전자 치료 제품의 신속한 승인과 국가의 생명 공학 인프라 투자를 통해 이 추세를 뒷받침하고 있습니다. VGXI사는 최근 텍사스주 콘로에 있는 GMP 시설의 FDA 사찰에 합격했습니다. 이 사찰에 의해 클라이언트의 생물 제제 승인 신청(BLA)이 승인되었습니다. VGXI사의 실적은 플라스미드 DNA 제조의 리더로서의 신뢰성을 강화하는 동시에 상업 단계의 유전자 치료, DNA 백신, RNA 기반 의약품을 가능하게 하는 데 있어서의 중요성을 강조하는 것입니다.

DNA 플라스미드 시장은 특수한 연구용 공급망에서 현대 치료 개발에 필수적인 백본으로 변모하고 있습니다. 따라서 유전자 치료용 플라스미드의 개발 증가가 DNA 플라스미드 제조 시장을 견인하고 있습니다.

경쟁업체 비교 분석에서는 제품 포트폴리오(제품 만족도, 제품 특징, 이용가능성), 최근 시장 동향(합병 및 인수, 신제품 출시 및 강화, 투자 및 자금 조달, 수상, 합의, 제휴 및 협력, 인지, 확대), 경쟁 구도의 보다 좋은 의사결정과 이해를 돕는 지역적 존재에 근거해 DNA 플라스미드 제조 시장을 평가 및 분류하고 있습니다. 본 보고서는 세계 DNA 플라스미드 제조 시장에서 주요 벤더의 최근 중요 동향과 혁신에 대해 심도 있게 조사하고 있습니다. 주요 시장 진입 기업으로는 WuXi Biologics Inc, Charles River Laboratories International Inc, Catalent Inc, Thermo Fisher Scientific Inc, AGC Biologics AS, Takara Bio Inc, SK pharmteco Inc, Sartorius, Creative Biogene, GenScript Biotech Corporation 등입니다.

DNA 플라스미드 제조 시장은 제품 유형에 따라 GMP 등급과 R&D 등급으로 나뉘어져 있습니다. GMP 등급 부문은 2024년 DNA 플라스미드 제조 시장에서 가장 큰 점유율을 차지했으며, 2024-2031년 가장 높은 CAGR을 기록할 것으로 예상됩니다. 용도별로는 DNA 플라스미드 제조 시장은 세포 및 유전자 치료, DNA 백신, 면역요법, 기타로 구분됩니다. 2024년에는 세포 및 유전자 치료 분야가 시장의 최대 점유율을 차지했습니다. 최종 사용자별로는 DNA 플라스미드 제조 시장은 제약 및 바이오 테크놀로지 기업, CRO 및 CDMO, 기타로 구분됩니다. 2024년에는 제약 및 바이오 테크놀로지 기업 부문이 최대 점유율을 차지했습니다.

DNA 플라스미드 제조 시장에서 사업을 전개하는 기업은 다양한 유기적 및 무기적 전략을 채용하고 있습니다. 유기적 전략에는 주로 제품 출시와 제품 승인이 포함됩니다. 무기적인 성장 전략으로는 인수, 제휴, 파트너십 등을 들 수 있습니다. 이러한 성장 전략을 통해 시장 기업은 사업을 확대하고 지리적 위상을 높이는 동시에 시장 전체의 성장에 기여할 수 있습니다. 게다가 인수나 제휴 등의 전략은 고객 기반을 강화하고 제품 포트폴리오를 확대하는 데 도움이 되고 있습니다. DNA 플라스미드 제조 시장의 주요 기업에 의한 중요한 발전의 몇 가지를 이하에 제시합니다.

2025년 3월 WuXi Biologics는 재조합 단백질과 플라스미드 DNA 생산을 촉진하는 EffiX 미생물 발현 플랫폼을 발표했습니다. EffiX는 높은 수율로 안정적인 비라이소제닉 대장균 발현 시스템에 대한 업계의 수요에 부응하도록 설계되었습니다. EffiX는 비모노클론항체(비Ab) 재조합 단백질 및 플라스미드 DNA를 개발하고 제조하기 위한 포괄적인 솔루션으로서 세계의 고객이 이용하고 있습니다. EffiX는 비 Ab 재조합 단백질에서 15g/L 이상, 플라스미드 DNA에서 1g/L 이상의 역가를 달성하고 여러 양식에서 고수율 생산을 실현합니다.

DNA 플라스미드 제조 시장-주요 시장 역학
시장 성장 촉진요인
- 유전자 치료용 플라스미드 개발 증가
- DNA 플라스미드 백신 개발 연구의 확대
시장 성장 억제요인
- 높은 제조 비용
시장 기회
- 개발 제조 수탁 기관(CDMO)의 확대
향후 동향
- 플라스미드 DNA 제조에서 디지털 기술의 통합
성장 촉진요인 및 억제요인의 영향

제6장 세계의 DNA 플라스미드 제조 시장 : 시장 분석

DNA 플라스미드 제조 시장의 수익(2021-2031년)
DNA 플라스미드 제조 시장 예측 분석

제7장 DNA 플라스미드 제조 시장 분석 : 제품 유형별

GMP 등급
R&D 등급

제8장 DNA 플라스미드 제조 시장 분석 : 용도별

세포 치료 및 유전자 치료
DNA 백신
면역요법
기타

제9장 DNA 플라스미드 제조 시장 분석 : 최종 사용자별

제약 및 바이오 테크놀러지 기업
CRO 및 CDMO
기타

제10장 DNA 플라스미드 제조 시장 : 지역별 분석

북미
- 미국
- 캐나다
- 멕시코
유럽
- 독일
- 영국
- 프랑스
- 이탈리아
- 스페인
- 기타 유럽
아시아태평양
- 중국
- 일본
- 인도
- 호주
- 한국
- 아시아태평양의 기타 국가
중동 및 아프리카
- 사우디아라비아
- 남아프리카
- 아랍에미리트(UAE)
- 기타 중동 및 아프리카
중남미
- 브라질
- 아르헨티나
- 기타 중남미

제11장 경쟁 구도

주요 기업별 히트맵 분석
기업 점유율 분석(2024년)

제12장 업계 정세

나이지리아 감염증 체외 진단약 시장에서의 성장 전략
유기적 성장 전략
무기적 성장 전략

제13장 기업 프로파일

Sartorius AG
WuXi Biologics Inc
Charles River Laboratories International Inc
Catalent Inc
Thermo Fisher Scientific Inc.
AGC Biologics AS
Takara Bio Inc
Creative Biogene
SK Pharmteco Inc
GenScript Biotech Corporation

제14장 부록

AJY 25.07.10

The DNA plasmid Manufacturing Market is expected to reach US$ 2,648.36 Mn by 2031 from US$ 686.38 Mn in 2024; the market is estimated to grow at a CAGR of 21.4% during 2025-2031. Major factors driving the market growth include increasing plasmid developments for gene therapy and growing research on DNA plasmid vaccine development. However, high manufacturing costs among the market deterrents.

The rise in the prevalence of genetic diseases, orphan diseases, and other cancers has accelerated the advancement of gene therapy technologies, which are based largely on plasmid DNA as the fundamental element. Plasmid DNA helps introduce genetic material into patients' cells. It acts as a non-viral vector to deliver therapeutic genes that can fix or replace faulty genes. Unlike viral vectors, plasmids are safer, easier to produce, and cheaper, making them popular in gene therapy.

As gene therapies transition from preclinical development to clinical trials and commercial launch, the demand for substantial quantities of high-purity, GMP-grade plasmid DNA has escalated significantly. In March 2023, Charles River Laboratories International, Inc. announced the launch of its off-the-shelf pHelper (Helper Plasmid) offering, which is designed to secure supply and streamline adeno-associated virus (AAV)-based gene therapy programs from early discovery through commercial manufacturing.

Growing partnerships between companies to meet the quality and regulatory demands of gene therapy pipelines. In 2022, Myrtelle and Forge Biologics announced a viral vector and plasmid DNA cGMP manufacturing partnership. Forge will provide research-grade and GMP-Pathway plasmid manufacturing services as well as cGMP adeno-associated viral (AAV) process development and scale-up manufacturing services for Myrtelle's program, Myr-201 (novel gene therapy for monogenic hearing loss).

Governments and regulatory agencies are also helping to drive this trend with expedited approvals for gene therapy products and national biotech infrastructure investment. VGXI, Inc. recently completed a successful FDA inspection at its GMP facility in Conroe, Texas. This inspection led to the approval of a client's Biologics License Application (BLA). VGXI's achievement reinforces its credibility as a plasmid DNA manufacturing leader as well as underscores its importance in enabling commercial-stage gene therapies, DNA vaccines, and RNA-based medicines.

The DNA plasmid market is transforming from a specialized research supply chain to an essential backbone of contemporary therapeutic development. Therefore, the increasing development of plasmid for gene therapy drives the DNA plasmid manufacturing market.

The comparative company analysis evaluates and categorizes the DNA plasmid Manufacturing Market based on product portfolio (product satisfaction, product features, and availability), recent market developments (merger & acquisition, new product launch & enhancement, investment & funding, award, agreement, collaboration, & partnership, recognition, and expansion), and geographic presence that aids better decision-making and understanding of the competitive landscape. The report profoundly explores the recent significant developments and innovations by the leading vendors in the global DNA plasmid Manufacturing Market. The key market players are WuXi Biologics Inc, Charles River Laboratories International Inc, Catalent Inc, Thermo Fisher Scientific Inc., AGC Biologics AS, Takara Bio Inc, SK pharmteco Inc, Sartorius, Creative Biogene, GenScript Biotech Corporation

The DNA plasmid Manufacturing Market, based on product type, is divided into GMP Grade and R&D grade. The GMP Grade segment held the largest share of the DNA plasmid Manufacturing Market in 2024, and it is expected to register the highest CAGR during 2024-2031. Based on Application, the DNA plasmid Manufacturing Market is segmented into Cell and Gene Therapy, DNA Vaccines, Immunotherapy, and Others. In 2024, the cell and gene therapy segment held the largest share of the market. Based on end user, the DNA plasmid Manufacturing Market is segmented into Pharmaceutical and Biotechnology Companies, CROs and CDMOs and Others. In 2024, the Pharmaceutical and Biotechnology Companies segment held the largest share of the market.

Various organic and inorganic strategies are adopted by companies operating in the DNA plasmid Manufacturing Market. The organic strategies mainly include product launches and product approvals. Inorganic growth strategies witnessed in the market are acquisitions, collaboration, and partnerships. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, along with contributing to the overall market growth. Furthermore, strategies such as acquisitions and partnerships helped strengthen their customer base and extend their product portfolios. A few of the significant developments by key players in the DNA plasmid Manufacturing Market are listed below.

In March 2025, WuXi Biologics Launched EffiX Microbial Expression Platform to Boost Recombinant Protein and Plasmid DNA Production. EffiX is designed to meet the industry's demand for a high-yield, stable, and non-lysogenic E. coli expression system. It serves as a comprehensive solution for developing and manufacturing non-monoclonal antibody (non-mAb) recombinant proteins and plasmid DNA for clients across the globe. EffiX delivers high-yield production across multiple modalities, achieving titers of over 15 g/L for non-mAb recombinant proteins and over 1 g/L for plasmid DNA.

1. Introduction

1.1 Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Analyst Market Outlook

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:
3.3 Assumptions and Limitations

4. DNA Plasmid Manufacturing Market Landscape

4.1 PEST Analysis

5. DNA Plasmid Manufacturing Market - Key Market Dynamics

5.1 DNA Plasmid Manufacturing Market - Key Market Dynamics
5.2 Market Drivers
- 5.2.1 Increasing Plasmid Developments for Gene Therapy
- 5.2.2 Growing Research on DNA Plasmid Vaccine Development
5.3 Market Restraints
- 5.3.1 High Manufacturing Costs
5.4 Market Opportunities
- 5.4.1 Expansion of Contract Development and Manufacturing Organizations (CDMOs)
5.5 Future Trends
- 5.5.1 Integration of Digital Technologies in Plasmid DNA Manufacturing
5.6 Impact of Drivers and Restraints:

6. DNA Plasmid Manufacturing Market - Global Market Analysis

6.1 DNA Plasmid Manufacturing Market Revenue (US$ Million), 2021-2031
6.2 DNA Plasmid Manufacturing Market Forecast Analysis

7. DNA Plasmid Manufacturing Market Analysis - by Product Type

7.1 GMP Grade
- 7.1.1 Overview
- 7.1.2 GMP Grade: DNA Plasmid Manufacturing Market - Revenue and Forecast to 2031 (US$ Million)
7.2 R&D grade
- 7.2.1 Overview
- 7.2.2 R&D grade: DNA Plasmid Manufacturing Market - Revenue and Forecast to 2031 (US$ Million)

8. DNA Plasmid Manufacturing Market Analysis - by Application

8.1 Cell and Gene Therapy
- 8.1.1 Overview
- 8.1.2 Cell and Gene Therapy: DNA Plasmid Manufacturing Market - Revenue and Forecast to 2031 (US$ Million)
8.2 DNA Vaccines
- 8.2.1 Overview
- 8.2.2 DNA Vaccines: DNA Plasmid Manufacturing Market - Revenue and Forecast to 2031 (US$ Million)
8.3 Immunotherapy
- 8.3.1 Overview
- 8.3.2 Immunotherapy: DNA Plasmid Manufacturing Market - Revenue and Forecast to 2031 (US$ Million)
8.4 Others
- 8.4.1 Overview
- 8.4.2 Others: DNA Plasmid Manufacturing Market - Revenue and Forecast to 2031 (US$ Million)

9. DNA Plasmid Manufacturing Market Analysis - by End User

9.1 Pharmaceutical and Biotechnology Companies
- 9.1.1 Overview
- 9.1.2 Pharmaceutical and Biotechnology Companies: DNA Plasmid Manufacturing Market - Revenue and Forecast to 2031 (US$ Million)
9.2 CROs and CDMOs
- 9.2.1 Overview
- 9.2.2 CROs and CDMOs: DNA Plasmid Manufacturing Market - Revenue and Forecast to 2031 (US$ Million)
9.3 Others
- 9.3.1 Overview
- 9.3.2 Others: DNA Plasmid Manufacturing Market - Revenue and Forecast to 2031 (US$ Million)

10. DNA Plasmid Manufacturing Market - Geographical Analysis

10.1 Overview
10.2 North America
- 10.2.1 North America DNA Plasmid Manufacturing Market Overview
- 10.2.2 North America: DNA Plasmid Manufacturing Market - Revenue, 2021-2031 (US$ Million)
- 10.2.3 North America: DNA Plasmid Manufacturing Market Breakdown, by Product Type
  - 10.2.3.1 North America: DNA Plasmid Manufacturing Market - Revenue and Forecast Analysis - by Product Type
- 10.2.4 North America: DNA Plasmid Manufacturing Market Breakdown, by Application
  - 10.2.4.1 North America: DNA Plasmid Manufacturing Market - Revenue and Forecast Analysis - by Application
- 10.2.5 North America: DNA Plasmid Manufacturing Market Breakdown, by End User
  - 10.2.5.1 North America: DNA Plasmid Manufacturing Market - Revenue and Forecast Analysis - by End User
- 10.2.6 North America: DNA Plasmid Manufacturing Market - Revenue and Forecast Analysis - by Country
  - 10.2.6.1 North America: DNA Plasmid Manufacturing Market - Revenue and Forecast Analysis - by Country
  - 10.2.6.2 United States: DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.2.6.2.1 United States: DNA Plasmid Manufacturing Market Breakdown, by Product Type
    - 10.2.6.2.2 United States: DNA Plasmid Manufacturing Market Breakdown, by Application
    - 10.2.6.2.3 United States: DNA Plasmid Manufacturing Market Breakdown, by End User
  - 10.2.6.3 Canada: DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.2.6.3.1 Canada: DNA Plasmid Manufacturing Market Breakdown, by Product Type
    - 10.2.6.3.2 Canada: DNA Plasmid Manufacturing Market Breakdown, by Application
    - 10.2.6.3.3 Canada: DNA Plasmid Manufacturing Market Breakdown, by End User
  - 10.2.6.4 Mexico: DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.2.6.4.1 Mexico: DNA Plasmid Manufacturing Market Breakdown, by Product Type
    - 10.2.6.4.2 Mexico: DNA Plasmid Manufacturing Market Breakdown, by Application
    - 10.2.6.4.3 Mexico: DNA Plasmid Manufacturing Market Breakdown, by End User
10.3 Europe
- 10.3.1 Europe DNA Plasmid Manufacturing Market Overview
- 10.3.2 Europe: DNA Plasmid Manufacturing Market - Revenue, 2021-2031 (US$ Million)
- 10.3.3 Europe: DNA Plasmid Manufacturing Market Breakdown, by Product Type
  - 10.3.3.1 Europe: DNA Plasmid Manufacturing Market - Revenue and Forecast Analysis - by Product Type
- 10.3.4 Europe: DNA Plasmid Manufacturing Market Breakdown, by Application
  - 10.3.4.1 Europe: DNA Plasmid Manufacturing Market - Revenue and Forecast Analysis - by Application
- 10.3.5 Europe: DNA Plasmid Manufacturing Market Breakdown, by End User
  - 10.3.5.1 Europe: DNA Plasmid Manufacturing Market - Revenue and Forecast Analysis - by End User
- 10.3.6 Europe: DNA Plasmid Manufacturing Market - Revenue and Forecast Analysis - by Country
  - 10.3.6.1 Europe: DNA Plasmid Manufacturing Market - Revenue and Forecast Analysis - by Country
  - 10.3.6.2 Germany: DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.3.6.2.1 Germany: DNA Plasmid Manufacturing Market Breakdown, by Product Type
    - 10.3.6.2.2 Germany: DNA Plasmid Manufacturing Market Breakdown, by Application
    - 10.3.6.2.3 Germany: DNA Plasmid Manufacturing Market Breakdown, by End User
  - 10.3.6.3 United Kingdom: DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.3.6.3.1 United Kingdom: DNA Plasmid Manufacturing Market Breakdown, by Product Type
    - 10.3.6.3.2 United Kingdom: DNA Plasmid Manufacturing Market Breakdown, by Application
    - 10.3.6.3.3 United Kingdom: DNA Plasmid Manufacturing Market Breakdown, by End User
  - 10.3.6.4 France: DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.3.6.4.1 France: DNA Plasmid Manufacturing Market Breakdown, by Product Type
    - 10.3.6.4.2 France: DNA Plasmid Manufacturing Market Breakdown, by Application
    - 10.3.6.4.3 France: DNA Plasmid Manufacturing Market Breakdown, by End User
  - 10.3.6.5 Italy: DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.3.6.5.1 Italy: DNA Plasmid Manufacturing Market Breakdown, by Product Type
    - 10.3.6.5.2 Italy: DNA Plasmid Manufacturing Market Breakdown, by Application
    - 10.3.6.5.3 Italy: DNA Plasmid Manufacturing Market Breakdown, by End User
  - 10.3.6.6 Spain: DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.3.6.6.1 Spain: DNA Plasmid Manufacturing Market Breakdown, by Product Type
    - 10.3.6.6.2 Spain: DNA Plasmid Manufacturing Market Breakdown, by Application
    - 10.3.6.6.3 Spain: DNA Plasmid Manufacturing Market Breakdown, by End User
  - 10.3.6.7 Rest of Europe: DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.3.6.7.1 Rest of Europe: DNA Plasmid Manufacturing Market Breakdown, by Product Type
    - 10.3.6.7.2 Rest of Europe: DNA Plasmid Manufacturing Market Breakdown, by Application
    - 10.3.6.7.3 Rest of Europe: DNA Plasmid Manufacturing Market Breakdown, by End User
10.4 Asia Pacific
- 10.4.1 Asia Pacific DNA Plasmid Manufacturing Market Overview
- 10.4.2 Asia Pacific: DNA Plasmid Manufacturing Market - Revenue, 2021-2031 (US$ Million)
- 10.4.3 Asia Pacific: DNA Plasmid Manufacturing Market Breakdown, by Product Type
  - 10.4.3.1 Asia Pacific: DNA Plasmid Manufacturing Market - Revenue and Forecast Analysis - by Product Type
- 10.4.4 Asia Pacific: DNA Plasmid Manufacturing Market Breakdown, by Application
  - 10.4.4.1 Asia Pacific: DNA Plasmid Manufacturing Market - Revenue and Forecast Analysis - by Application
- 10.4.5 Asia Pacific: DNA Plasmid Manufacturing Market Breakdown, by End User
  - 10.4.5.1 Asia Pacific: DNA Plasmid Manufacturing Market - Revenue and Forecast Analysis - by End User
- 10.4.6 Asia Pacific: DNA Plasmid Manufacturing Market - Revenue and Forecast Analysis - by Country
  - 10.4.6.1 Asia Pacific: DNA Plasmid Manufacturing Market - Revenue and Forecast Analysis - by Country
  - 10.4.6.2 China: DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.4.6.2.1 China: DNA Plasmid Manufacturing Market Breakdown, by Product Type
    - 10.4.6.2.2 China: DNA Plasmid Manufacturing Market Breakdown, by Application
    - 10.4.6.2.3 China: DNA Plasmid Manufacturing Market Breakdown, by End User
  - 10.4.6.3 Japan: DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.4.6.3.1 Japan: DNA Plasmid Manufacturing Market Breakdown, by Product Type
    - 10.4.6.3.2 Japan: DNA Plasmid Manufacturing Market Breakdown, by Application
    - 10.4.6.3.3 Japan: DNA Plasmid Manufacturing Market Breakdown, by End User
  - 10.4.6.4 India: DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.4.6.4.1 India: DNA Plasmid Manufacturing Market Breakdown, by Product Type
    - 10.4.6.4.2 India: DNA Plasmid Manufacturing Market Breakdown, by Application
    - 10.4.6.4.3 India: DNA Plasmid Manufacturing Market Breakdown, by End User
  - 10.4.6.5 Australia: DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.4.6.5.1 Australia: DNA Plasmid Manufacturing Market Breakdown, by Product Type
    - 10.4.6.5.2 Australia: DNA Plasmid Manufacturing Market Breakdown, by Application
    - 10.4.6.5.3 Australia: DNA Plasmid Manufacturing Market Breakdown, by End User
  - 10.4.6.6 South Korea: DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.4.6.6.1 South Korea: DNA Plasmid Manufacturing Market Breakdown, by Product Type
    - 10.4.6.6.2 South Korea: DNA Plasmid Manufacturing Market Breakdown, by Application
    - 10.4.6.6.3 South Korea: DNA Plasmid Manufacturing Market Breakdown, by End User
  - 10.4.6.7 Rest of APAC: DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.4.6.7.1 Rest of APAC: DNA Plasmid Manufacturing Market Breakdown, by Product Type
    - 10.4.6.7.2 Rest of APAC: DNA Plasmid Manufacturing Market Breakdown, by Application
    - 10.4.6.7.3 Rest of APAC: DNA Plasmid Manufacturing Market Breakdown, by End User
10.5 Middle East and Africa
- 10.5.1 Middle East and Africa DNA Plasmid Manufacturing Market Overview
- 10.5.2 Middle East and Africa: DNA Plasmid Manufacturing Market - Revenue, 2021-2031 (US$ Million)
- 10.5.3 Middle East and Africa: DNA Plasmid Manufacturing Market Breakdown, by Product Type
  - 10.5.3.1 Middle East and Africa: DNA Plasmid Manufacturing Market - Revenue and Forecast Analysis - by Product Type
- 10.5.4 Middle East and Africa: DNA Plasmid Manufacturing Market Breakdown, by Application
  - 10.5.4.1 Middle East and Africa: DNA Plasmid Manufacturing Market - Revenue and Forecast Analysis - by Application
- 10.5.5 Middle East and Africa: DNA Plasmid Manufacturing Market Breakdown, by End User
  - 10.5.5.1 Middle East and Africa: DNA Plasmid Manufacturing Market - Revenue and Forecast Analysis - by End User
- 10.5.6 Middle East and Africa: DNA Plasmid Manufacturing Market - Revenue and Forecast Analysis - by Country
  - 10.5.6.1 Middle East and Africa: DNA Plasmid Manufacturing Market - Revenue and Forecast Analysis - by Country
  - 10.5.6.2 Saudi Arabia: DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.5.6.2.1 Saudi Arabia: DNA Plasmid Manufacturing Market Breakdown, by Product Type
    - 10.5.6.2.2 Saudi Arabia: DNA Plasmid Manufacturing Market Breakdown, by Application
    - 10.5.6.2.3 Saudi Arabia: DNA Plasmid Manufacturing Market Breakdown, by End User
  - 10.5.6.3 South Africa: DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.5.6.3.1 South Africa: DNA Plasmid Manufacturing Market Breakdown, by Product Type
    - 10.5.6.3.2 South Africa: DNA Plasmid Manufacturing Market Breakdown, by Application
    - 10.5.6.3.3 South Africa: DNA Plasmid Manufacturing Market Breakdown, by End User
  - 10.5.6.4 United Arab Emirates: DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.5.6.4.1 United Arab Emirates: DNA Plasmid Manufacturing Market Breakdown, by Product Type
    - 10.5.6.4.2 United Arab Emirates: DNA Plasmid Manufacturing Market Breakdown, by Application
    - 10.5.6.4.3 United Arab Emirates: DNA Plasmid Manufacturing Market Breakdown, by End User
  - 10.5.6.5 Rest of Middle East and Africa: DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.5.6.5.1 Rest of Middle East and Africa: DNA Plasmid Manufacturing Market Breakdown, by Product Type
    - 10.5.6.5.2 Rest of Middle East and Africa: DNA Plasmid Manufacturing Market Breakdown, by Application
    - 10.5.6.5.3 Rest of Middle East and Africa: DNA Plasmid Manufacturing Market Breakdown, by End User
10.6 South and Central America
- 10.6.1 South and Central America DNA Plasmid Manufacturing Market Overview
- 10.6.2 South and Central America: DNA Plasmid Manufacturing Market - Revenue, 2021-2031 (US$ Million)
- 10.6.3 South and Central America: DNA Plasmid Manufacturing Market Breakdown, by Product Type
  - 10.6.3.1 South and Central America: DNA Plasmid Manufacturing Market - Revenue and Forecast Analysis - by Product Type
- 10.6.4 South and Central America: DNA Plasmid Manufacturing Market Breakdown, by Application
  - 10.6.4.1 South and Central America: DNA Plasmid Manufacturing Market - Revenue and Forecast Analysis - by Application
- 10.6.5 South and Central America: DNA Plasmid Manufacturing Market Breakdown, by End User
  - 10.6.5.1 South and Central America: DNA Plasmid Manufacturing Market - Revenue and Forecast Analysis - by End User
- 10.6.6 South and Central America: DNA Plasmid Manufacturing Market - Revenue and Forecast Analysis - by Country
  - 10.6.6.1 South and Central America: DNA Plasmid Manufacturing Market - Revenue and Forecast Analysis - by Country
  - 10.6.6.2 Brazil: DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.6.6.2.1 Brazil: DNA Plasmid Manufacturing Market Breakdown, by Product Type
    - 10.6.6.2.2 Brazil: DNA Plasmid Manufacturing Market Breakdown, by Application
    - 10.6.6.2.3 Brazil: DNA Plasmid Manufacturing Market Breakdown, by End User
  - 10.6.6.3 Argentina: DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.6.6.3.1 Argentina: DNA Plasmid Manufacturing Market Breakdown, by Product Type
    - 10.6.6.3.2 Argentina: DNA Plasmid Manufacturing Market Breakdown, by Application
    - 10.6.6.3.3 Argentina: DNA Plasmid Manufacturing Market Breakdown, by End User
  - 10.6.6.4 Rest of South and Central America: DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.6.6.4.1 Rest of South and Central America: DNA Plasmid Manufacturing Market Breakdown, by Product Type
    - 10.6.6.4.2 Rest of South and Central America: DNA Plasmid Manufacturing Market Breakdown, by Application
    - 10.6.6.4.3 Rest of South and Central America: DNA Plasmid Manufacturing Market Breakdown, by End User

11. Competitive Landscape

11.1 Heat Map Analysis by Key Players
11.2 Company Market Share Analysis, 2024

12. Industry Landscape

12.1 Overview
12.2 Growth Strategies in the Nigeria Infectious Disease In-Vitro Diagnostics Market
12.3 Organic Growth Strategies
- 12.3.1 Overview
12.4 Inorganic Growth Strategies
- 12.4.1 Overview

13. Company Profiles

13.1 Sartorius AG
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 WuXi Biologics Inc
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Charles River Laboratories International Inc
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Catalent Inc
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Thermo Fisher Scientific Inc.
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 AGC Biologics AS
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Takara Bio Inc
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
13.8 Creative Biogene
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 SK Pharmteco Inc
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 GenScript Biotech Corporation
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments

14. Appendix

14.1 About The Insight Partners
14.2 Glossary of Terms